

Report on Operations 2018-2019: Strategic acquisition and strong closing of the year

CELLINK publishes the quarterly report for the period 1st of June 2019 – 31st of August 2019 and for the full year of operations 2018-2019. The report is available on the company's website: <https://cellink.com/investors/> This press release presents a summary of the report.

Fourth quarter

- Net sales amounted to SEK 31,997 (16,465) thousand, corresponding to a growth of 94%, of which 23% was organic growth, compared to the fourth quarter of the previous fiscal year.
- Operating profit before depreciation (EBITDA) amounted to SEK -2,435 (1,069) thousand, corresponding to a negative margin (6.5 %).
- Net income amounted to SEK -1,745 (583) thousand, generating earnings per share after dilution of SEK -0.19 (0.07).

Full year

- Net sales amounted to SEK 105,457 (45,337) thousand, corresponding to a growth of 133%, of which 92% was organic growth.
- Operating profit before depreciation (EBITDA) amounted to SEK 3,551 (2,997) thousand, corresponding to a margin of 3.2% (6.6%).
- Net income amounted to SEK 581 (1,183) thousand, generating earnings per share after dilution of SEK 0.07 (0.14).

Events during the quarter (Jun. 2019-Aug. 2019)

- On June 18, CELLINK raised 148.5 mSEK in capital. The issue was directed to institutional investors as a fast and effective way to finance a potential acquisition.
- On June 24, CELLINK collaborated with a team of researchers at Uppsala University to send 3D-bioprinted neural crest stem cells to space.
- On July 11, CELLINK was granted a patent for "Clean Chamber Technology for 3D Printers and Bioprinters" from the Korean Patent Office.
- On August 5, CELLINK acquired cytena GmbH, a company that produces single-cell dispensing technology.
- On August 13, CELLINK was granted a patent for a temperature-controlled printed technology from the European Patent Office.

Events during the other financial year (Sept. 2018-May 2019)

- On October 17, CELLINK launched two new series of bioink as well as an expansion of a current series.
- On November 6, CELLINK launched a new series of bioink and extended three existing product series.
- On December 1, CELLINK completed its acquisition of German company Dispendix GmbH for a

purchase price of 5 million EUR.

- On December 4, CELLINK announced a collaboration with MedImmune to use CELLINK's technology for drug discovery.
- On December 5, CELLINK signed a partnership with Prellis Biologics Inc. to commercialize holographic bioprinting technology.
- On January 28, the European Union granted CELLINK 5 mSEK in project funding.
- On February 4, CELLINK launched CELLCYTE X, a new product enabling real-time cell microscopy.
- On February 19, CELLINK was granted a patent for "3D printer and a method for 3D printing of a construct."
- On March 18, CELLINK launched Lumen X, a bioprinter that uses digital light processing.
- On May 2, CELLINK launched new tissue model kits.
- On May 27, it was announced that CELLINK would work with Umeå University and GE Healthcare to develop transplantable skin models to improve burn patients' quality of life.

Events after the end of the period

- On October 17, CELLINK launched two new series of bioink as well as an expansion of a current series.
- On September 3, CELLINK launched the BIO X6, a product designed to be the most flexible six-printhead platform on the market.
- On October 1, CELLINK was granted a design patent for BIO X.
- On October 2, it was announced that CELLINK received the Merck Innovation Award for designing technology to enhance pharmaceutical research.
- On October 14, the company announced that CELLINK's 4 founders was appointed entrepreneurs of the year in Sweden in 2019

For further information, please contact:

Erik Gatenholm, CEO
Phone: EU +46 73 267 00 00
US +1 (650) 515 5566
Email: eg@cellink.com

Gusten Danielsson, CFO
Phone: +46 70 991 86 04
US +1 (857) 332 2138
Email: gd@cellink.com

Important information

This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on October 24, 2019 at 08:30 CET.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About CELLINK

[CELLINK](#) is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company's certified adviser, available by phone at +46 846 383 00 and by email at certifiedadviser@penser.se.
at: certifiedadviser@penser.se.